久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Nanobiotix soars as late-phase cancer trial hits endpoint fiercebiotech
    June 25, 2018
    A phase 2/3 trial of Nanobiotix’s NBTXR3 in soft tissue sarcoma has?met?(PDF) its primary endpoint. The top-line success against the pathological complete response rate endpoint sent Nanobiotix’s stock up by more than 50%.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service